Pilot Study of Venlafaxine Extended Release (XR) in the Treatment of Panic Disorder (PD) in Comparison to Paroxetine.

Wyeth is now a wholly owned subsidiary of Pfizer0 sites70 target enrollmentJanuary 2005

ConditionsPanic Disorders

DrugsVENLAFAXINE Paroxetine

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Panic Disorders
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Enrollment: 70
Primary Endpoint: To evaluate the improvement of social function following therapy with Venlafaxine extended release (XR)in the Treatment of Panic Disorder in comparison to Paroxetine.
Status: Completed
Last Updated: 16 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

The purpose of this pilot study is to evaluate the improvement in social function following therapy with venlafaxine extended release (XR) in the treatment of panic disorder (PD) in comparison to paroxetine. An additional purpose of this pilot study is to obtain the tolerability of using venlafaxine extended release (XR) in the treatment of panic disorder (PD) in comparison to paroxetine.

Registry

clinicaltrials.gov

Start Date

January 2005

End Date

April 2006

Last Updated

16 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

Eligibility Criteria

Inclusion Criteria

•Meet DSM IV criteria for Panic Disorder (with or without agoraphobia) for at least 3 months before study day
•Have a minimum of 8 full-symptom panic attacks during the 4 weeks before the screening visit.
•Provide a written informed consent

Exclusion Criteria

•Treatment with Venlafaxine within 6 months of study day 1, as well Paroxetine
•Known hypersensitivity to Venlafaxine or related compounds as well to Paroxetine.
•Psychopharmacologic drugs within 14 days of study day 1

Outcomes

Primary Outcomes

To evaluate the improvement of social function following therapy with Venlafaxine extended release (XR)in the Treatment of Panic Disorder in comparison to Paroxetine.